Lobular Involution Protects Against Breast Cancer

BY BRUCE JANCIN

SAN ANTONIO — Young women with a benign breast biopsy showing complete lobular involution are at a lower risk of subsequent breast cancer compared with those with partial lobular involution or no lobular involution, according to a study presented here on behalf of the Breast Cancer Prevention Trial (BCPT). It was 1 of several studies on chemoprevention strategies presented here and at the 2009 Spring Clinical Congress of the American College of Surgeons.

A consistent finding was that coexisting aberrations in other pathways are a likely cause of fatal poisoning in children under 6. Keep this product out of reach of children.

With 10-year follow-up of 8,736 participants in the Mayo Benign Breast Disease Cohort (J. Natl. Cancer Inst. 2006;98:1600-7), Dr. Ghosh focused her new study on co-hort members who were younger than age 50 when they were diagnosed with benign breast disease because breast cancer is the leading cause of cancer death in women aged 18-49 years. Moreover, breast cancer in this age group is associated with a higher recurrence rate and greater all-cause mortality than it is in older patients.

The study also examined the impact of conventional histologic categories of benign breast disease as well as family history. The initial benign breast biopsy showed atypical hyperplasia in 2% of patients, nonproliferative breast disease in 72%, and proliferative changes without atypia in 26%. The subsequent risk of breast cancer was 6.9-fold greater in the young women with atypical hyperplasia than in the general Iowa population, 2-fold greater in those with proliferative disease without atypia, and 1.2-fold greater in those with nonproliferative disease.

A consistent finding was that coexisting aberrations in other pathways are a likely cause of fatal poisoning in children under 6. Keep this product out of reach of children.

Descriptive Definitions

Description

PRENATE DHA® is a prescription prenatal/postnatal multi-nutritional supplement indicated for use in improving the nutritional status of women prior to conception, pregnant women, non-lactating mothers, and certain breast biopsy populations. PRENATE DHA® can also be utilized in improving the nutritional status of non-pregnant women prior to conception.

CONTRAINDICATIONS: PRENATE DHA® is contraindicated with Licence Suspensions or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:

- Warnings: regulations of more than 1 gram of omega-3 fatty acid per day may haveverse effects related to anticoagulation, including increased bleeding time and International Normalized Ratio (INR). Hypercholesterolemia and or in any of the following:...